On November 3, 2022 Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, reported its third quarter 2022 results (Press release, Targovax, NOV 3, 2022, View Source [SID1234622865]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Members of Targovax’s executive management team will give an online presentation to investors, analysts and the press at 10:00 CET today (details below).

THIRD QUARTER 2022 HIGHLIGHTS
ONCOS-102
The study protocol for the planned multi-cohort phase 2 in melanoma was approved by the US FDA
The phase 1b melanoma study results were selected for oral presentation at the prestigious Society for Immunotherapy in Cancer (SITC) (Free SITC Whitepaper) annual meeting
The phase 1b melanoma study results were published in the high-impact oncology journal "Clinical Cancer Research"
CircRNA pipeline program
Key technical proof-of-concept data were established for the circRNA program
Mutant KRAS platform
Preparations progressed for the TG01 mutant KRAS trials – one in Norway and one in the USA
Erik Digman Wiklund, CEO commented: "It is a very exciting time to lead Targovax. We are building a great pipeline and have established a robust development strategy for our clinical stage products. During the third quarter we made important progress on all three of our strategic pillars, and Targovax is in a strong position to build success for both the clinical and pre-clinical parts of our portfolio."